EUVIMEDEUVIMED entdecken
Crossref

Beyond Amyloids: Neuroprotective Potential of Betanin and its Derivatives Against Alpha-Synuclein Aggregates and ROS Overload in Parkinson’s Disease

Ayda Ghahari, Alireza Alikhanian, Fatemeh Akhond Solaei, Arghavan Fattahi, Hamdam Hourfar, Anett Schallmey, Mehdi Mohammadi, Dina Morshedi

Journal of Molecular Neuroscience · 2026

DOI: 10.1007/s12031-026-02534-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Molecular Neuroscience, 2026. Verfasst von Ayda Ghahari und 7 weiteren Autor:innen. Beteiligte Einrichtung: Bioprocess Engineering Department, Institute of Industrial and Environmental Biotechnology, National Institute of Genetic Engineering and Biotechnolo…. Hauptthemen laut MEDLINE: Betacyanins, alpha-Synuclein, Neuroprotective Agents, Reactive Oxygen Species. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: National Institute of Genetic Engineering and Biotechnology and the Alexander von Humboldt Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aggregation of alpha-synuclein (αSN) is a key pathological feature of Parkinson's disease (PD), leading to neural cell death via reactive oxygen species (ROS) overload and activation of downstream neurotoxic pathways. Betanin, a beetroot-derived small molecule, has exhibited antioxidant and neuroprotective properties. In this study, three betaxanthins-Bxn-A, Bxn-B, and Bxn-C-were chemically synthesized from betanin to enhance its therapeutic properties. Betaxanthin Bxn-A effectively reduced intracellular ROS levels without cytotoxicity, even at 500 µM. Additionally, betanin and its derivatives revealed neuroprotective effects, including significant reductions in apoptosis, preservation of mitochondrial membrane potential, modulated autophagy, and enhanced cell viability in PD-model cells. In terms of aggregation inhibition, betaxanthins Bxn-A and Bxn-B significantly reduced αSN aggregation compared to the control after 48 h of incubation. Betaxanthin Bxn-A also triggered disaggregation of existing aggregates and inhibited formation of large, insoluble species. Moreover, αSN aggregation and disaggregation products formed in the presence of betanin or its derivatives exhibited significantly lower cytotoxicity than those formed in their absence. Specifically, cells treated with aggregates formed in the presence of 50 µM betaxanthin Bxn-B showed 100% viability, while those treated with disaggregation products formed in the presence of 100 µM betaxanthin Bxn-A showed 20% greater viability than those treated with untreated disaggregates. Molecular docking revealed interactions between betaxanthins and key αSN residues, suggesting destabilization mechanisms. Docking analyses with five ROS-PPI network key proteins-C5, CDC42, BCL2, CDKN1A, and CDKN1B-indicated potential roles in inhibiting oxidative stress-related pathways. Drug-likeness predictions indicated that the derivatives enhanced pharmacological potential, making them promising candidates for PD treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Betacyaninsalpha-SynucleinNeuroprotective AgentsReactive Oxygen SpeciesParkinson DiseaseHumansAnimalsApoptosisMembrane Potential, MitochondrialProtein AggregatesAutophagyMolecular Docking SimulationRats

Stichwörter der Autor:innen

Alpha-SynucleinBeetrootBetaninFibrillationNeuroprotectiveParkinson’s disease

Substanzen

Betacyaninsalpha-SynucleinbetaninNeuroprotective AgentsReactive Oxygen SpeciesProtein Aggregates

Autor:innen und Institutionen

  • Bioprocess Engineering Department, Institute of Industrial and Environmental Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran.
  • School of Biology, College of Science, University of Tehran, Tehran, Iran.
  • Institute for Biochemistry, Biotechnology and Bioinformatics, Technische Universität Braunschweig, Braunschweig, Germany.
  • Bioprocess Engineering Department, Institute of Industrial and Environmental Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran. m.mohammadi@nigeb.ac.ir.
  • Bioprocess Engineering Department, Institute of Industrial and Environmental Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran. morshedi@nigeb.ac.ir.

Förderung

  • National Institute of Genetic Engineering and Biotechnology and the Alexander von Humboldt Foundation

Zitieren

APA

Ghahari, A., Alikhanian, A., Solaei, F. A., Fattahi, A., Hourfar, H., Schallmey, A., Mohammadi, M., & Morshedi, D. (2026). Beyond Amyloids: Neuroprotective Potential of Betanin and its Derivatives Against Alpha-Synuclein Aggregates and ROS Overload in Parkinson’s Disease. Journal of Molecular Neuroscience. https://doi.org/10.1007/s12031-026-02534-9

Vancouver

Ghahari A, Alikhanian A, Solaei FA, Fattahi A, Hourfar H, Schallmey A, et al. Beyond Amyloids: Neuroprotective Potential of Betanin and its Derivatives Against Alpha-Synuclein Aggregates and ROS Overload in Parkinson’s Disease. Journal of Molecular Neuroscience. 2026. doi:10.1007/s12031-026-02534-9

BibTeX
@article{Ghahari2026,
  author = {Ghahari, Ayda and Alikhanian, Alireza and Solaei, Fatemeh Akhond and Fattahi, Arghavan and Hourfar, Hamdam and Schallmey, Anett and Mohammadi, Mehdi and Morshedi, Dina},
  title = {Beyond Amyloids: Neuroprotective Potential of Betanin and its Derivatives Against Alpha-Synuclein Aggregates and ROS Overload in Parkinson’s Disease},
  journal = {Journal of Molecular Neuroscience},
  year = {2026},
  doi = {10.1007/s12031-026-02534-9}
}
Kostenlos starten →